Laniakea@ReCaS: exploring the potential of customisable Galaxy on-demand instances as a cloud-based service.
Bioinformatics
Cloud computing
Covid-19
ELIXIR
Galaxy
Laniakea
NGS
SARS-Cov-2
Software environment
Journal
BMC bioinformatics
ISSN: 1471-2105
Titre abrégé: BMC Bioinformatics
Pays: England
ID NLM: 100965194
Informations de publication
Date de publication:
08 Nov 2021
08 Nov 2021
Historique:
received:
12
09
2021
accepted:
24
09
2021
entrez:
9
11
2021
pubmed:
10
11
2021
medline:
11
11
2021
Statut:
epublish
Résumé
Improving the availability and usability of data and analytical tools is a critical precondition for further advancing modern biological and biomedical research. For instance, one of the many ramifications of the COVID-19 global pandemic has been to make even more evident the importance of having bioinformatics tools and data readily actionable by researchers through convenient access points and supported by adequate IT infrastructures. One of the most successful efforts in improving the availability and usability of bioinformatics tools and data is represented by the Galaxy workflow manager and its thriving community. In 2020 we introduced Laniakea, a software platform conceived to streamline the configuration and deployment of "on-demand" Galaxy instances over the cloud. By facilitating the set-up and configuration of Galaxy web servers, Laniakea provides researchers with a powerful and highly customisable platform for executing complex bioinformatics analyses. The system can be accessed through a dedicated and user-friendly web interface that allows the Galaxy web server's initial configuration and deployment. "Laniakea@ReCaS", the first instance of a Laniakea-based service, is managed by ELIXIR-IT and was officially launched in February 2020, after about one year of development and testing that involved several users. Researchers can request access to Laniakea@ReCaS through an open-ended call for use-cases. Ten project proposals have been accepted since then, totalling 18 Galaxy on-demand virtual servers that employ ~ 100 CPUs, ~ 250 GB of RAM and ~ 5 TB of storage and serve several different communities and purposes. Herein, we present eight use cases demonstrating the versatility of the platform. During this first year of activity, the Laniakea-based service emerged as a flexible platform that facilitated the rapid development of bioinformatics tools, the efficient delivery of training activities, and the provision of public bioinformatics services in different settings, including food safety and clinical research. Laniakea@ReCaS provides a proof of concept of how enabling access to appropriate, reliable IT resources and ready-to-use bioinformatics tools can considerably streamline researchers' work.
Sections du résumé
BACKGROUND
BACKGROUND
Improving the availability and usability of data and analytical tools is a critical precondition for further advancing modern biological and biomedical research. For instance, one of the many ramifications of the COVID-19 global pandemic has been to make even more evident the importance of having bioinformatics tools and data readily actionable by researchers through convenient access points and supported by adequate IT infrastructures. One of the most successful efforts in improving the availability and usability of bioinformatics tools and data is represented by the Galaxy workflow manager and its thriving community. In 2020 we introduced Laniakea, a software platform conceived to streamline the configuration and deployment of "on-demand" Galaxy instances over the cloud. By facilitating the set-up and configuration of Galaxy web servers, Laniakea provides researchers with a powerful and highly customisable platform for executing complex bioinformatics analyses. The system can be accessed through a dedicated and user-friendly web interface that allows the Galaxy web server's initial configuration and deployment.
RESULTS
RESULTS
"Laniakea@ReCaS", the first instance of a Laniakea-based service, is managed by ELIXIR-IT and was officially launched in February 2020, after about one year of development and testing that involved several users. Researchers can request access to Laniakea@ReCaS through an open-ended call for use-cases. Ten project proposals have been accepted since then, totalling 18 Galaxy on-demand virtual servers that employ ~ 100 CPUs, ~ 250 GB of RAM and ~ 5 TB of storage and serve several different communities and purposes. Herein, we present eight use cases demonstrating the versatility of the platform.
CONCLUSIONS
CONCLUSIONS
During this first year of activity, the Laniakea-based service emerged as a flexible platform that facilitated the rapid development of bioinformatics tools, the efficient delivery of training activities, and the provision of public bioinformatics services in different settings, including food safety and clinical research. Laniakea@ReCaS provides a proof of concept of how enabling access to appropriate, reliable IT resources and ready-to-use bioinformatics tools can considerably streamline researchers' work.
Identifiants
pubmed: 34749633
doi: 10.1186/s12859-021-04401-3
pii: 10.1186/s12859-021-04401-3
pmc: PMC8574934
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
544Subventions
Organisme : Horizon 2020 Framework Programme
ID : 653549
Organisme : Horizon 2020 Framework Programme
ID : 857650
Organisme : Horizon 2020 Framework Programme
ID : 824087
Informations de copyright
© 2021. The Author(s).
Références
Bioinformatics. 2011 Feb 15;27(4):578-9
pubmed: 21149342
Cell Syst. 2018 Jun 27;6(6):631-635
pubmed: 29953862
Bioinformatics. 2021 Apr 1;36(22-23):5522-5523
pubmed: 33346830
BMC Genomics. 2018 Feb 5;19(1):120
pubmed: 29402227
Microb Genom. 2018 Mar;4(3):
pubmed: 29543149
Front Microbiol. 2021 Jan 12;11:599524
pubmed: 33510722
Nucleic Acids Res. 2020 Jan 8;48(D1):D17-D23
pubmed: 31701143
J Virol. 2007 Jan;81(1):20-9
pubmed: 16928755
J Microbiol Methods. 2015 May;112:87-91
pubmed: 25794901
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Genome Biol. 2015 Jun 26;16:134
pubmed: 26112015
EMBO J. 2021 Mar 15;40(6):e107409
pubmed: 33565128
Methods Mol Biol. 2019;1979:425-432
pubmed: 31028652
BMC Bioinformatics. 2020 Aug 21;21(Suppl 10):352
pubmed: 32838759
Nucleic Acids Res. 2017 Jan 4;45(D1):D566-D573
pubmed: 27789705
Genome Biol. 2019 Aug 12;20(1):164
pubmed: 31405382
Antimicrob Agents Chemother. 2014;58(1):212-20
pubmed: 24145532
Dis Model Mech. 2020 Sep 18;13(9):
pubmed: 32620541
Nat Protoc. 2014 Jan;9(1):171-81
pubmed: 24385147
J Clin Microbiol. 2012 Sep;50(9):2918-31
pubmed: 22740710
Science. 2016 Jul 1;353(6294):78-82
pubmed: 27365449
Bioinformatics. 2021 Apr 5;36(24):5590-5599
pubmed: 33367501
Nat Rev Genet. 2017 Oct;18(10):599-612
pubmed: 28804138
NPJ Syst Biol Appl. 2021 Jan 5;7(1):1
pubmed: 33402683
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
Nature. 2020 May;581(7809):434-443
pubmed: 32461654
Nucleic Acids Res. 2013 Jul;41(Web Server issue):W557-61
pubmed: 23640334
PLoS Comput Biol. 2013 Apr;9(4):e1003031
pubmed: 23592973
Nucleic Acids Res. 2020 Jul 2;48(W1):W395-W402
pubmed: 32479607
Gigascience. 2019 Sep 1;8(9):
pubmed: 31494672
BMC Bioinformatics. 2018 Oct 15;19(Suppl 10):349
pubmed: 30367595
J Antimicrob Chemother. 2012 Nov;67(11):2640-4
pubmed: 22782487
BMC Bioinformatics. 2004 Jun 06;5:72
pubmed: 15180906
Mol Aspects Med. 2018 Feb;59:114-122
pubmed: 28712804
Mol Cell. 2019 Jan 3;73(1):130-142.e5
pubmed: 30472192
PLoS Comput Biol. 2017 Jun 8;13(6):e1005595
pubmed: 28594827
Nat Med. 2020 Mar;26(3):317-319
pubmed: 32108160
Am J Hum Genet. 2017 Feb 2;100(2):267-280
pubmed: 28132688
Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5
pubmed: 23193258
Gigascience. 2015 Aug 25;4:39
pubmed: 26336600
Front Genet. 2012 Mar 15;3:35
pubmed: 22435069
Brief Bioinform. 2014 Mar;15(2):256-78
pubmed: 23341494
Euro Surveill. 2017 Mar 30;22(13):
pubmed: 28382917
Int J Med Microbiol. 2003 Feb;292(7-8):477-86
pubmed: 12635930
Sci Rep. 2019 Nov 26;9(1):17550
pubmed: 31772190
Microb Drug Resist. 2011 Sep;17(3):479-84
pubmed: 21568753
Science. 2015 Jan 9;347(6218):1254806
pubmed: 25525159
Nucleic Acids Res. 2010 Jul;38(Web Server issue):W677-82
pubmed: 20501605
Nature. 2021 Jan;589(7842):337-338
pubmed: 33452508
BMC Genomics. 2011 Oct 14;12:507
pubmed: 21999641
Antimicrob Agents Chemother. 2014 Jul;58(7):3895-903
pubmed: 24777092
Clin Microbiol Rev. 2017 Oct;30(4):1015-1063
pubmed: 28855266
Gigascience. 2020 Apr 1;9(4):
pubmed: 32252069
Nucleic Acids Res. 2017 Jul 3;45(W1):W560-W566
pubmed: 28582575
Bioinformatics. 2014 Jul 1;30(13):1928-9
pubmed: 24618473
Gigascience. 2016 Jul 11;5(1):30
pubmed: 27401684
Nature. 2021 Mar;591(7848):30-33
pubmed: 33649511
Eur J Hum Genet. 2020 Feb;28(2):165-173
pubmed: 31527858
Antimicrob Agents Chemother. 2019 Oct 22;63(11):
pubmed: 31427293
Hum Mutat. 2018 Jun;39(6):756-773
pubmed: 29633501
J Clin Microbiol. 2008 Feb;46(2):685-8
pubmed: 18094130
Appl Environ Microbiol. 2017 Aug 17;83(17):
pubmed: 28625989
Nat Rev Genet. 2011 Aug 18;12(9):628-40
pubmed: 21850043
Brief Bioinform. 2021 Mar 22;22(2):631-641
pubmed: 33416890
Brief Bioinform. 2021 Mar 22;22(2):616-630
pubmed: 33279989
Adv Appl Bioinform Chem. 2015 Nov 13;8:23-35
pubmed: 26604801